Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Chinese Patent Office

Generated: December 13, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020191

« Back to Dashboard

NDA 020191 describes ALOMIDE, which is a drug marketed by Novartis Pharms Corp and is included in one NDA. It is available from one supplier. Additional details are available on the ALOMIDE profile page.

The generic ingredient in ALOMIDE is lodoxamide tromethamine. One supplier is listed for this compound. Additional details are available on the lodoxamide tromethamine profile page.

Summary for 020191

Therapeutic Class:Ophthalmic Agents

Pharmacology for NDA: 020191

Physiological EffectDecreased Histamine Release

Suppliers and Packaging for NDA: 020191

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ALOMIDE lodoxamide tromethamine SOLUTION/DROPS;OPHTHALMIC 020191 NDA Alcon Laboratories, Inc. 0065-0345 0065-0345-10 1 BOTTLE, PLASTIC in 1 CARTON (0065-0345-10) > 10 mL in 1 BOTTLE, PLASTIC

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:SOLUTION/DROPS;OPHTHALMICStrengthEQ 0.1% BASE
Approval Date:Sep 23, 1993TE:RLD:Yes

Expired Orange Book Patents for NDA: 020191

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis Pharms CorpALOMIDElodoxamide tromethamineSOLUTION/DROPS;OPHTHALMIC020191-001Sep 23, 1993► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Argus Health
Queensland Health
Express Scripts
Cantor Fitzgerald
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch: